This guideline is an update of the previous 2016 version. It takes account of significant new evidence and provides guidance for component specification and transfusing foetuses, neonates and older children. Recommendations are made where evidence exists, and key practice points are given where guidance is based on panel consensus. In some clinical situations, a modified approach to the recommendations may be appropriate, including for patients with certain rare disorders. 

The clinical section focused largely on transfusion indications and administration. The laboratory section contain mainly information on pre-transfusion testing and component selection. A summary of blood component specifications and typical transfusion volumes and rates is in Appendix 1, including the safely features for specific fetal/neonatal infant components that are in addition to those for older children and adults.  

Declaration of Interests

The BSH paid the expenses incurred during the writing of this Guideline. All authors have made a declaration of interests to the BSH and Task Force Chairs.